Hedgehog信号通路激活与慢性淋巴细胞白血病早期疾病进展相关
对841例初治慢性淋巴细胞白血病(CLL)患者白血病细胞进行103个白血病相关基因的靶向测序,89例(11%)存在Hedgehog(Hh)信号通路相关基因突变,且与GLI1表达显著相关(χ2检验,P<.0001)。38%无突变病例亦为GLI1阳性;GLI1阳性CLL细胞患者的中位无治疗生存期短于GLI1阴性者,且不依赖IGHV突变状态。GLI1抑制剂GANT61对GLI1阳性CLL细胞具有高度细胞毒性。
要点
- 841例初治CLL中11%(89例)存在Hh通路相关基因突变,与GLI1表达显著相关(P<.0001)。
- 38%无Hh通路基因突变的病例也呈GLI1阳性,提示Hh通路激活更广泛。
- GLI1阳性CLL细胞患者中位无治疗生存期较短,不依赖IGHV突变状态。
核心结论
- 很大比例CLL患者白血病细胞存在Hh信号通路激活,与早期疾病进展相关,并增强对GLI1抑制的敏感性。
研究设计与样本
- 对841例初治CLL患者白血病细胞进行103个白血病相关基因的靶向测序,并分析GLI1表达及体外药物敏感性。
主要发现
- 841例中89例(11%)存在Hh信号通路相关基因突变,突变与GLI1表达显著相关(χ2检验,P<.0001)。
- 38%无Hh通路基因突变的病例也呈GLI1阳性。
- GLI1阳性CLL细胞患者的中位无治疗生存期短于GLI1阴性者,且不依赖IGHV突变状态。
- GLI1抑制剂GANT61对GLI1阳性CLL细胞具有高度细胞毒性。
关键数值与推荐
- Hh通路相关基因突变与GLI1表达关联的χ2检验P<.0001。
- 无Hh通路基因突变病例中GLI1阳性比例为38%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted sequencing of 103 leukemia-associated genes in leukemia cells from 841 treatment-naive patients with chronic lymphocytic leukemia (CLL) identified 89 (11%) patients as having CLL cells with mutations in genes encoding proteins that putatively are involved in hedgehog (Hh) signaling. Consistent with this finding, there was a significant association between the presence of these mutations and the expression of GLI1 (χ2 test, P < .0001), reflecting activation of the Hh pathway. However, we discovered that 38% of cases without identified mutations also were GLI1+ Patients with GLI1+ CLL cells had a shorter median treatment-free survival than patients with CLL cells lacking expression of GLI1 independent of IGHV mutation status. We found that GANT61, a small molecule that can inhibit GLI1, was highly cytotoxic for GLI1+ CLL cells relative to that of CLL cells without GLI1. Collectively, this study shows that a large proportion of patients have CLL cells with activated Hh signaling, which is associated with early disease progression and enhanced sensitivity to inhibition of GLI1.
引用
- Ghia EM, Rassenti LZ, Neuberg DS, et al. Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood. 2019. PMID: 30923040. doi:10.1182/blood-2018-09-873695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。